A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

NCT03330197 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision due to slow accrual

Conditions

Pediatric Brain Tumor
Diffuse Intrinsic Pontine Glioma

Interventions

BIOLOGICAL: Ad-RTS-hIL-12
DRUG: Oral Veledimex - Arm 1 (Pediatric Brain Tumor)
DRUG: Oral Veledimex - Arm 2 (DIPG)

Sponsor

Alaunos Therapeutics